Artificially cloaked viral nanovaccine for cancer immunotherapy
Cancer therapy using oncolytic virus has shown pre-clinical and clinical efficacy. Here, the authors report ExtraCRAd, an oncolytic virus cloaked with tumour cell membrane and report its therapeutic effects in vitro and in vivo in multiple mouse tumour models.
Main Authors: | Manlio Fusciello, Flavia Fontana, Siri Tähtinen, Cristian Capasso, Sara Feola, Beatriz Martins, Jacopo Chiaro, Karita Peltonen, Leena Ylösmäki, Erkko Ylösmäki, Firas Hamdan, Otto K. Kari, Joseph Ndika, Harri Alenius, Arto Urtti, Jouni T. Hirvonen, Hélder A. Santos, Vincenzo Cerullo |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2019-12-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-13744-8 |
Similar Items
-
A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella
by: Manlio Fusciello, et al.
Published: (2022-06-01) -
GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses
by: Firas Hamdan, et al.
Published: (2021-03-01) -
Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses
by: Firas Hamdan, et al.
Published: (2023-03-01) -
Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine
by: Sara Feola, et al.
Published: (2022-04-01) -
Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors
by: S. Feola, et al.
Published: (2018-08-01)